Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Moore R, Kyd JM, Carzino R, Armstrong D, Grimwood K, Otczyk DC, Cripps AW.

Hum Vaccin Immunother. 2013 Mar;9(3):506-14. Epub 2012 Dec 18.

2.

Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.

Cui Z, Han D, Sun X, Zhang M, Feng X, Sun C, Gu J, Tong C, Lei L, Han W.

Appl Microbiol Biotechnol. 2015 Jan;99(2):667-80. doi: 10.1007/s00253-014-6147-z. Epub 2014 Nov 11.

PMID:
25381907
4.

Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.

Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, Worgall S.

Vaccine. 2011 Mar 3;29(11):2131-9. doi: 10.1016/j.vaccine.2010.12.087. Epub 2011 Jan 6.

5.

Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.

Bumann D, Behre C, Behre K, Herz S, Gewecke B, Gessner JE, von Specht BU, Baumann U.

Vaccine. 2010 Jan 8;28(3):707-13. doi: 10.1016/j.vaccine.2009.10.080. Epub 2009 Nov 1.

PMID:
19887136
6.
7.

A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.

Westritschnig K, Hochreiter R, Wallner G, Firbas C, Schwameis M, Jilma B.

Hum Vaccin Immunother. 2014;10(1):170-83. doi: 10.4161/hv.26565. Epub 2013 Sep 24.

8.

Pseudomonas aeruginosa: immune status in patients with cystic fibrosis.

Doggett RG, Harrison GM.

Infect Immun. 1972 Oct;6(4):628-35.

9.

A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Weimer ET, Lu H, Kock ND, Wozniak DJ, Mizel SB.

Infect Immun. 2009 Jun;77(6):2356-66. doi: 10.1128/IAI.00054-09. Epub 2009 Apr 6.

11.
12.
13.

Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors.

West SE, Zeng L, Lee BL, Kosorok MR, Laxova A, Rock MJ, Splaingard MJ, Farrell PM.

JAMA. 2002 Jun 12;287(22):2958-67.

PMID:
12052125
15.

Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Hollsing AE, Granström M, Vasil ML, Wretlind B, Strandvik B.

J Clin Microbiol. 1987 Oct;25(10):1868-74.

16.
17.
18.

Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia.

Brauner A, Cryz SJ, Granström M, Hanson HS, Löfstrand L, Strandvik B, Wretlind B.

Eur J Clin Microbiol Infect Dis. 1993 Jun;12(6):430-6.

PMID:
8359163
19.

Strategies of Pseudomonas aeruginosa to colonize and to persist in the cystic fibrosis lung.

Kubesch P, Lingner M, Grothues D, Wehsling M, Tümmler B.

Scand J Gastroenterol Suppl. 1988;143:77-80.

PMID:
3133755
20.

Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.

Pressler T, Pandey JP, Espersen F, Pedersen SS, Fomsgaard A, Koch C, Høiby N.

Clin Exp Immunol. 1992 Nov;90(2):209-14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk